MX9800414A - Medicamentos. - Google Patents
Medicamentos.Info
- Publication number
- MX9800414A MX9800414A MX9800414A MX9800414A MX9800414A MX 9800414 A MX9800414 A MX 9800414A MX 9800414 A MX9800414 A MX 9800414A MX 9800414 A MX9800414 A MX 9800414A MX 9800414 A MX9800414 A MX 9800414A
- Authority
- MX
- Mexico
- Prior art keywords
- cgmp
- phosphodiesterase inhibitors
- treat impotence
- impotence
- pyrazino
- Prior art date
Links
- 201000001881 impotence Diseases 0.000 title abstract 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- XZCSUPWHWMDLEC-LKNMKHRSSA-N (3s,6r,12ar)-6-(1,3-benzodioxol-5-yl)-2,3-dimethyl-6,7,12,12a-tetrahydro-3h-pyrazino[1,2-b]$b-carboline-1,4-quinone Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3C(=O)N(C)[C@H](C(N32)=O)C)=C1 XZCSUPWHWMDLEC-LKNMKHRSSA-N 0.000 abstract 1
- FFCZQVKVWGGQFB-UHFFFAOYSA-N 9h-pyrido[3,4-b]indole-1,4-dione Chemical compound N1C2=CC=CC=C2C2=C1C(=O)N=CC2=O FFCZQVKVWGGQFB-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Credit Cards Or The Like (AREA)
- Networks Using Active Elements (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El uso de (6R,12aR)-2,3,6,7,12,12a-hexahidro-2-metil-6-(3,4- metilendioxifenil)-pirazino[2', 1':6,1]pirido[3,4-b]indol-1,4-diona; (3S,6R,12aR)-2,3,6,7,12,12a-hexahidro-2,3-dimetil- 6-(3,4-metilendioxifenil)-pirazino[2',1':6,1]pirid o[3,4-b]indol-1,4-diona, y las sales y solvatos fisiologicamente aceptables de éstos en el tratamiento de la impotencia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9514464.8A GB9514464D0 (en) | 1995-07-14 | 1995-07-14 | Medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9800414A true MX9800414A (es) | 1998-06-30 |
Family
ID=10777695
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02009987A MXPA02009987A (es) | 1995-07-14 | 1996-07-11 | Uso de inhibidores de gcmp-fosfodiesterasa. |
MX9800414A MX9800414A (es) | 1995-07-14 | 1998-01-13 | Medicamentos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02009987A MXPA02009987A (es) | 1995-07-14 | 1996-07-11 | Uso de inhibidores de gcmp-fosfodiesterasa. |
Country Status (25)
Country | Link |
---|---|
US (2) | US6140329A (es) |
EP (1) | EP0839040B1 (es) |
JP (1) | JP4169365B2 (es) |
CN (2) | CN1112928C (es) |
AT (1) | ATE327756T1 (es) |
AU (1) | AU704955B2 (es) |
BR (1) | BR9609758A (es) |
CA (1) | CA2226784C (es) |
CY (2) | CY2563B1 (es) |
CZ (1) | CZ289686B6 (es) |
DE (1) | DE69636193T2 (es) |
DK (1) | DK0839040T3 (es) |
ES (1) | ES2267111T3 (es) |
GB (1) | GB9514464D0 (es) |
HK (1) | HK1005363A1 (es) |
HU (1) | HU228369B1 (es) |
IL (1) | IL122870A (es) |
MX (2) | MXPA02009987A (es) |
NO (1) | NO314685B1 (es) |
PL (2) | PL185737B1 (es) |
PT (1) | PT839040E (es) |
RU (1) | RU2181288C2 (es) |
SI (1) | SI0839040T1 (es) |
SK (2) | SK284494B6 (es) |
WO (1) | WO1997003675A1 (es) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9423910D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
EP2295436A1 (de) | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren |
AU2641199A (en) * | 1998-02-27 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies for erectile dysfunction |
WO1999059584A1 (en) * | 1998-05-20 | 1999-11-25 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
EP0967284A1 (en) * | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
JP2000178204A (ja) * | 1998-10-05 | 2000-06-27 | Eisai Co Ltd | ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤 |
US6743443B1 (en) | 1998-10-05 | 2004-06-01 | Eisai Co., Ltd. | Tablets immediately disintegrating in the oral cavity |
JP2000191518A (ja) * | 1998-10-19 | 2000-07-11 | Eisai Co Ltd | 溶解性の改善された口腔内速崩壊性錠剤 |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
WO2000053148A2 (en) * | 1999-03-08 | 2000-09-14 | Merck & Co., Inc. | Methods and compositions for treating erectile dysfunction |
WO2000066114A1 (en) * | 1999-04-30 | 2000-11-09 | Lilly Icos Llc | Treatment of female arousal disorder |
US6943166B1 (en) * | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
IL135817A0 (en) * | 1999-04-30 | 2001-05-20 | Lilly Icos Llc | Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles |
US6451807B1 (en) * | 1999-04-30 | 2002-09-17 | Lilly Icos, Llc. | Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
ES2310166T3 (es) * | 1999-08-03 | 2009-01-01 | Lilly Icos Llc | Composicion farmaceutica que contiene tadalafil. |
US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
GB9922124D0 (en) * | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6436944B1 (en) * | 1999-09-30 | 2002-08-20 | Pfizer Inc. | Combination effective for the treatment of impotence |
AP2002002455A0 (en) | 1999-10-11 | 2002-06-30 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors. |
UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
UA72611C2 (uk) * | 2000-05-17 | 2005-03-15 | Орто-Макнейл Фармацевтикал, Інк. | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази |
EP1289989A2 (en) | 2000-06-07 | 2003-03-12 | Lilly Icos LLC | Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione |
WO2001094347A1 (en) * | 2000-06-08 | 2001-12-13 | Lilly Icos Llc | Tetracyclic diketopiperazine compounds as pdev inhibitors |
AU2001261707A1 (en) * | 2000-06-23 | 2002-01-08 | Lilly Icos Llc | Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives |
CA2413510C (en) | 2000-06-26 | 2007-12-11 | Lilly Icos Llc | Condensed pyrazindione derivatives |
MXPA03000887A (es) * | 2000-08-02 | 2004-04-05 | Lilly Icos Llc | Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa. |
AU8444401A (en) * | 2000-09-06 | 2002-03-22 | Tanabe Seiyaku Co | Preparations for oral administration |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
ATE297926T1 (de) * | 2000-10-02 | 2005-07-15 | Lilly Icos Llc | Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen |
US6960587B2 (en) | 2000-11-08 | 2005-11-01 | Lilly Icos Llc | Condensed pyrazindione derivatives as PDE inhibitors |
KR100750554B1 (ko) * | 2001-02-15 | 2007-08-20 | 다나베 세이야꾸 가부시키가이샤 | 구강 내 속붕괴성 정제 |
DE10118305A1 (de) * | 2001-04-12 | 2002-10-17 | Bayer Ag | Zusammensetzungen zur nasalen Applikation |
WO2002083631A1 (en) | 2001-04-13 | 2002-10-24 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
US7098209B2 (en) * | 2001-06-05 | 2006-08-29 | Lilly Icos Llc | Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives |
JP4450365B2 (ja) * | 2001-08-28 | 2010-04-14 | シェーリング コーポレイション | 多環式グアニンホスホジエステラーゼv阻害剤 |
US20030087963A1 (en) | 2001-09-13 | 2003-05-08 | Senanayake Chris H. | Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites |
CA2465893A1 (en) * | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
ES2289159T3 (es) | 2001-11-14 | 2008-02-01 | Ortho-Mcneil Pharmaceutical Corporation | Derivados tetraciclicos sustituidos de pirroloquinolona utilizados como inhibidores de fosfodiesterasa. |
CA2469075C (en) * | 2001-12-20 | 2011-09-13 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
DE10232113A1 (de) | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
WO2004011029A2 (en) * | 2002-07-26 | 2004-02-05 | Adams Kenneth W | Pharmaceutical compositions for penis enlargement |
WO2005068464A2 (en) * | 2003-12-15 | 2005-07-28 | Cadila Healthcare Limited | Process for preparing tadalafil and its intermediates |
AU2005239962B2 (en) | 2004-05-11 | 2011-07-07 | Eb Ip Lybrido B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
US20060235005A1 (en) * | 2005-04-14 | 2006-10-19 | Oak Labs, Corp. | Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
US20070010525A1 (en) * | 2005-06-27 | 2007-01-11 | Meyer Jackson | Method and compositions for modulating neuropeptide hormone secretion |
BRPI0615972A2 (pt) | 2005-07-29 | 2011-05-31 | Concert Pharmaceuticals Inc | composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
JP2009507925A (ja) * | 2005-09-13 | 2009-02-26 | エラン ファーマ インターナショナル リミテッド | ナノ粒子タダラフィル製剤 |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007124045A2 (en) * | 2006-04-20 | 2007-11-01 | Ampla Pharmaceuticals, Inc. | Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
KR101140110B1 (ko) * | 2006-07-07 | 2012-06-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물 |
BRPI0716604A2 (pt) | 2006-09-08 | 2013-04-09 | Braincells Inc | combinaÇÕes contendo um derivado de 4-acilaminopiridina |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
EP2120570B1 (en) | 2007-02-12 | 2012-05-16 | DMI Biosciences, Inc. | Treatment of comorbid premature ejaculation and erectile dysfunction |
NZ579170A (en) | 2007-02-12 | 2012-05-25 | Dmi Biosciences Inc | Reducing side effects of tramadol |
WO2008134557A2 (en) * | 2007-04-25 | 2008-11-06 | Teva Pharmaceutical Industries Ltd. | Solid dosage forms |
DE102007028869A1 (de) * | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
US20090181975A1 (en) * | 2008-01-15 | 2009-07-16 | Forest Laboratories Holdings Limited | Nebivolol in the treatment of sexual dysfunction |
ES2553897T3 (es) | 2008-05-02 | 2015-12-14 | Gilead Sciences, Inc. | El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
AR073522A1 (es) | 2008-09-30 | 2010-11-10 | Biolab Sanus Farmaceutica Ltda | Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US8586587B2 (en) | 2009-02-26 | 2013-11-19 | Thar Pharmaceuticals, Inc. | Crystalline molecular complex of tadalafil and methylparaben |
DE102009033396A1 (de) | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
US10610528B2 (en) * | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
UY33535A (es) * | 2010-08-13 | 2011-12-01 | Biolab Sanus Farmaceutuca Limitada | Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona |
CN104011047A (zh) | 2011-10-14 | 2014-08-27 | 阵列生物制药公司 | 选择性herb2抑制剂arry-380的多晶型物和含有它们的药物组合物 |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
MX357741B (es) * | 2012-07-06 | 2018-07-23 | Laboratorios Senosiain S A De C V Star | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
EP2903619B1 (en) | 2012-10-05 | 2019-06-05 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
EP3054951A4 (en) * | 2013-10-07 | 2017-05-10 | Millennium Pharmaceuticals, Inc. | Inhibitor of breast cancer resistance protein (bcrp) |
US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
ES2749433T3 (es) | 2014-06-23 | 2020-03-20 | Celgene Corp | Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática |
CN104086546B (zh) * | 2014-07-14 | 2016-08-17 | 福建广生堂药业股份有限公司 | 他达拉非的药用酸盐及其制备方法 |
WO2018112258A1 (en) | 2016-12-14 | 2018-06-21 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
PT3510997T (pt) | 2018-01-10 | 2020-10-07 | Gap S A | Cápsulas de gelatina mole compreendendo uma suspensão de tadalafil |
WO2019241585A1 (en) | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644384A (en) * | 1969-06-09 | 1972-02-22 | Sterling Drug Inc | Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives |
US3717638A (en) * | 1971-03-11 | 1973-02-20 | Sterling Drug Inc | 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR |
US3917599A (en) * | 1973-03-30 | 1975-11-04 | Council Scient Ind Res | 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles |
GB1454171A (en) * | 1973-10-19 | 1976-10-27 | Council Scient Ind Res | Tetracyclic compounds |
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
GR79603B (es) * | 1982-07-24 | 1984-10-31 | Pfizer | |
IT1217190B (it) * | 1988-04-22 | 1990-03-14 | Recordati Chem Pharm | Composti utili per il trattamento e diagnosi di disfunzioni frettili |
EP0357122A3 (en) * | 1988-08-29 | 1991-10-23 | Duphar International Research B.V | Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties |
DE3830096A1 (de) * | 1988-09-03 | 1990-03-15 | Hoechst Ag | Piperazindione mit psychotroper wirkung |
FR2649613B1 (fr) * | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
JPH0344324A (ja) * | 1989-07-13 | 1991-02-26 | Kazuoki Tsuchiya | 性機能賦活剤 |
ATE113839T1 (de) * | 1990-05-31 | 1994-11-15 | Pfizer | Arzneimittel gegen impotenz. |
US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
GB9012469D0 (en) * | 1990-06-05 | 1990-07-25 | Glaxo Group Ltd | Medicaments |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
-
1995
- 1995-07-14 GB GBGB9514464.8A patent/GB9514464D0/en active Pending
-
1996
- 1996-07-11 SK SK1259-2003A patent/SK284494B6/sk not_active IP Right Cessation
- 1996-07-11 US US08/981,989 patent/US6140329A/en not_active Expired - Lifetime
- 1996-07-11 BR BR9609758A patent/BR9609758A/pt unknown
- 1996-07-11 CA CA002226784A patent/CA2226784C/en not_active Expired - Lifetime
- 1996-07-11 AU AU64191/96A patent/AU704955B2/en not_active Expired
- 1996-07-11 DK DK96923985T patent/DK0839040T3/da active
- 1996-07-11 HU HU9900065A patent/HU228369B1/hu unknown
- 1996-07-11 MX MXPA02009987A patent/MXPA02009987A/es active IP Right Grant
- 1996-07-11 CN CN96196723A patent/CN1112928C/zh not_active Expired - Lifetime
- 1996-07-11 SK SK39-98A patent/SK284141B6/sk not_active IP Right Cessation
- 1996-07-11 WO PCT/EP1996/003024 patent/WO1997003675A1/en active IP Right Grant
- 1996-07-11 CN CNB021557918A patent/CN1311828C/zh not_active Expired - Lifetime
- 1996-07-11 IL IL12287096A patent/IL122870A/en not_active IP Right Cessation
- 1996-07-11 PL PL96324495A patent/PL185737B1/pl unknown
- 1996-07-11 RU RU98102398/14A patent/RU2181288C2/ru active
- 1996-07-11 CZ CZ199833A patent/CZ289686B6/cs not_active IP Right Cessation
- 1996-07-11 JP JP50624897A patent/JP4169365B2/ja not_active Expired - Lifetime
- 1996-07-11 EP EP96923985A patent/EP0839040B1/en not_active Expired - Lifetime
- 1996-07-11 PL PL96357665A patent/PL185999B1/pl unknown
- 1996-07-11 AT AT96923985T patent/ATE327756T1/de active
- 1996-07-11 ES ES96923985T patent/ES2267111T3/es not_active Expired - Lifetime
- 1996-07-11 DE DE69636193T patent/DE69636193T2/de not_active Expired - Lifetime
- 1996-07-11 SI SI9630740T patent/SI0839040T1/sl unknown
- 1996-07-11 PT PT96923985T patent/PT839040E/pt unknown
-
1998
- 1998-01-13 MX MX9800414A patent/MX9800414A/es unknown
- 1998-01-13 NO NO19980153A patent/NO314685B1/no not_active IP Right Cessation
- 1998-05-28 HK HK98104622A patent/HK1005363A1/xx not_active IP Right Cessation
-
2000
- 2000-05-18 US US09/573,905 patent/US6608065B1/en not_active Expired - Lifetime
-
2006
- 2006-09-04 CY CY0600024A patent/CY2563B1/xx unknown
- 2006-11-02 CY CY200600007C patent/CY2006007I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9800414A (es) | Medicamentos. | |
GB9511220D0 (en) | Solid dispersions | |
CA2400554A1 (en) | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors | |
MX9702307A (es) | Pirrolo (2,3-d)pirimidinas y su uso. | |
AU2514792A (en) | 1-substituted 1h-imidazo(4,5-c)quinolin-4-amines; intermediate and pharmaceutical compositions | |
MD1616F2 (en) | Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment | |
MD1632F2 (en) | Bicyclic compounds, method of inhibiting the tyrosine kinases receptors as epidermal growth factor, pharmaceutical composition, methods of preventing blastocyte implantation and treatment of mammals | |
TR199900308T2 (xx) | Tiyenopirimidinler | |
ES2175079T3 (es) | Derivados de indol utiles como inhibidores de cgmp-pde. | |
AU5624699A (en) | Use of 5ht-6 antagonists | |
BG102789A (en) | Parimido[5,4-d]pyrimidines, medicamentous forms containing them, their application and method for their preparation | |
WO2001094345A3 (en) | Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione | |
NZ509855A (en) | The use of pyrido[1,2-a]pyrazine derivatives for the treatment of Parkinson's disease, ADHD and microadenomas | |
CA2328280A1 (en) | Thienopyrimidines | |
BG105714A (en) | Use of imidazolo[1,5-a]-pyrido[3,2-e]pyrazinons as medicaments | |
TW327171B (en) | 2-heteroaryl-5 for prevention or treatment of HIV infection | |
TW216795B (en) | 3-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazoline derivatives, the preparation and use thereof | |
AU1823995A (en) | Arteriosclerosis depressant | |
CA2412594A1 (en) | Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives | |
DE60111553D1 (de) | Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen | |
AU6846300A (en) | Use of cyamemazine for cold turkey benzodiazepine treatment | |
AU2001292498A1 (en) | 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain | |
MX9706878A (es) | Pirazolo [3,4-d] pirimidin-4-onas 6-arilo y composiciones y metodos para su uso. | |
ATE376993T1 (de) | Herstellung von 3,5,7ö-1h-imidazo 1,5-aöimidazol-2(3h)-on-verb ndungen | |
MD980248A (ro) | Derivaţi ai carbolinei |